IL2 and cancer: The Th1 immune response can be usually inhibited in a variety of malignant tumors, which manifests as the down-regulation of TNF-α, IL-2, IFN-γ and IL-2, and defecting the proliferation of cytotoxic T cells, macrophages and NK cells.